



**GENE THERAPY FORUM**  
MARCH 23-25, 2026 | BOSTON, USA



3RD INTERNATIONAL CONFERENCE ON

# HUMAN **GENE** THERAPY CONFERENCE

**MARCH**  
23-25, 2026

VENUE: HILTON BOSTON  
BACK BAY BOSTON  
MASSACHUSETTS, USA

SUPPORTED BY

**MB** Meet  
BOSTON

[www.genetherapyconference.com](http://www.genetherapyconference.com)

# INSTRUCTIONS FOR SPEAKERS

1. **Invited Talks:** Invited speakers will be allotted 17 minutes to present their results, followed by a 3-minute discussion period.
2. **Oral Talks:** Oral speakers will be allotted 12 minutes to present their results, followed by a 3-minute discussion period.
3. Please do not exceed the allotted time slot.
4. Speakers should have their presentations saved on a USB memory stick.
5. It is suggested to email a copy of the presentations to us as back up.
6. Please prepare the presentation in PPT files, PDF is not recommended.
7. **Basic AV setup will be provided:** laser pointer, cordless mike, desktop mike, sound system.
8. Laptops equipped with Windows 10, Office 2010 Pro English (Word, Powerpoint, Excel) and Adobe Reader are provided.
9. If your presentation files contain movies, please make sure that they are well formatted and connected to the main files. You may check your slides during the breaks.
10. Projectors are equipped with standard VGA connection ports. Mac users should bring their own adapter cord.
11. Please re-check this program prior to the conference to confirm if any changes have been made to your session.
12. Conference volunteers will move the mic during Q&A. Audience with questions may raise hand to receive the mic.

# INSTRUCTIONS FOR E-POSTER

1. Poster must be prepared in PowerPoint (Max 2 slides).
2. Use high-resolution images and readable fonts.
3. Each presenter will have 7 minutes to briefly explain their poster during the poster session, Followed by 3 minutes for Q&A.

## CO-CHAIRS



### **MITRA TAVAKKOLI, MD, PHARM D**

VP of clinical development and Head  
of Drug Safety at Sangamo  
Therapeutics, USA



### **ARUN SRIVASTAVA**

Professor  
University of Florida College of  
Medicine



### **JEFF CHAFFIN**

Market Access Strategy and Contracting  
Consultant Miles Payer Strategy  
USA



### **HILDEGUND ERTL**

Professor  
The Wistar Institute  
USA



### **SOPHIE BLONDEL**

Founder and CEO  
Fox-Bio, France

# DAY-1, 23 MARCH, 2026

**09:00–09:45** Registrations

**09:45–10:00** Welcoming Speech: Conference Co-chairs

## Session I: Technology Innovations & Gene Delivery Platforms Session Chair: Tristan Jervis, Impact Shine Communications, UK

**10:00–10:20** Title: Expanding Gene Editing Beyond the Liver  
**Devyn Smith**, Arbor Biotechnologies, USA

**10:20–10:40** Title: Development of Capsid- and Genome-Modified NextGen AAV Vectors; Nuclease-Free Gene Editing With AAV-B19 Hybrid and Chimeric Vectors  
**Arun Srivastava**, University of Florida College of Medicine, USA

**10:40–11:00** Title: Mitigating Immune Responses to AAV Vector-Mediated Gene Transfer  
**Hildegund Ertl**, The Wistar Institute, USA

## 11:00–11:30 COFFEE BREAK

**11:30–11:50** Title: Technology Innovations  
**Jeremy Shelley**, Form Bio, USA

**11:50–12:10** Title: Gene Delivery Technologies  
**Molly McGlaughlin**, Revolution Biomanufacturing Inc, USA

**12:10–12:30** Title: Gene Delivery Technologies  
**Daozhan Yu**, AAVnerGene, USA

**12:30–12:50** Title: Gene Editing Therapy Development: Platform Design and Manufacturing Readiness  
**Kok-Seong**, Independent Consultant, USA

## Session 2: Clinical Development, Trials & Therapeutic Applications Session Chair: Arun Srivastava, University of Florida College of Medicine, USA

**12:50–13:10** Title: Isaralgagene Civaparovec (ST-920) Shows Positive Mean Annualized eGFR Slope in Adults With Fabry Disease: Topline Results From the Registrational Phase 1/2 STAAR Gene Therapy Study and Long-Term Follow-Up Study  
**Mitra Tavakkoli**, Sangamo Therapeutics, USA

## 13:10–14:10 LUNCH BREAK

**14:10–14:30** Title: Gene Therapy for X-linked Retinitis Pigmentosa  
**Daniel C. Chung**, Beacon Therapeutics, USA

**14:30–14:50** Title: Rare Diseases and Early Phase Units  
**Chris A. Learn**, Parexel, USA  
**Anita Mardian**, Parexel, USA

**14:50–15:10** Title: Targeting DNA Methyltransferase to Restore Vision After Traumatic Optic Nerve Injury  
**Wai Lydia Tai**, MEEI, Harvard Medical School, USA

**15:10-15:30** **Title:** Genetic Testing in Clinical Trials  
**Rachel Smith**, Parexel, UK

**15:30-16:00** **COFFEE BREAK**

**PANEL DISCUSSIONS**

**16:00-17:00** **Title:** Building Durable Patient Partnerships  
**Melissa Penn**, Bayer Pharmaceuticals, USA  
**Daya Verma**, Novartis, USA  
**Chris A. Learn**, Parexel, USA  
**Tristan Jervis**, Impact Shine Communications, UK

**17:00-18:00** **Networking Cocktails**

# DAY-2, 24 MARCH, 2026

## Session 3: Regulatory Landscape, Quality & Compliance Session Chair: Tristan Jervis, Impact Shine Communications, UK

**10:00–10:20** **Title:** FDA Inspection & GMP Expectations  
**Alonza Cruse**, Office of Pharmaceutical Quality Operations, USA

**10:20–10:40** **Title:** PAIs vs Surveillance Inspections  
**Deyaa Shaheen**, Xfda Pharma Advisors Consultanting Services, USA

**10:40–11:00** **Title:** Concurrent US and EU Approvals Roadmap  
**Rajiv Gangurde**, Parexel, USA

### 11:00–11:30 COFFEE BREAK

**11:30–11:50** **Title:** Proof of Concept to IND Readiness: How IND-Enabling Materials De-risk Regulatory and Funding Milestone  
**Emily Moran**, 3LB Consulting, LLC, USA

**11:50–12:10** **Title:** TBA (Online)  
**Nagendra Chemuturi**, Eli Lilly and Company, USA

## Session 4: Collaborations, Partnerships & Crisis Strategy

**12:10–12:30** **Title:** Technology Innovations & Collaborations (Industry Scale-Up Focus)  
**Rachel Legmann**, Repligen, USA

**12:30–12:50** **Title:** Issues & Crisis Management  
**Tristan Jervis**, Impact Shine Communications, UK

### 12:50–14:30 LUNCH BREAK

**14:30–14:50** **Title:** Overcoming Barriers to Cell and Gene Therapy Commercialization  
**Curt Kugel**, ZS, USA

**14:50–15:10** **Title:** Parent and Advocacy Perspective  
**Amanda Moore**, Angelman Syndrome Foundation, USA

**15:10–15:30** **Title:** TBA (Online)  
**Caitlin Collin**, Sparing Vision, USA

### 15:30–16:00 COFFEE BREAK

### PANEL DISCUSSIONS

**16:00–16:40** **Title:** Analytical QC and Potency Assurance Challenges  
**Patrick Starremans**, Solid Biosciences Inc, USA  
**Hongwei Zhang**, HZ Independent BioConsulting, USA  
**Rajiv Gangurde**, Parexel, USA  
**Tristan Jervis**, Impact Shine Communications, UK

## 16:40–17:00 E-POSTER PRESENTATIONS

**GT01** **Title:** Manufacturing and Supply Chain Strategies

**José Vázquez**, c-LEcta GmbH, Germany

**GT02** **Title:** TBA

**Mehmet Karaca**, Sarepta Therapeutics, USA

# DAY-3, 25 MARCH, 2026

## Session 5: Manufacturing, Supply Chain & Commercialization Strategy

**10:00–10:20** **Title:** Scalable and Execution-Ready GT Manufacturing

**Mihir Shukla**, Biopharma Consulting Solutions, LLC, USA

**10:20–10:40** **Title:** Low-Cost AAV Vector Manufacturing

**Larry Forman**, CHO Plus, Inc, USA

**10:40–11:00** **Title:** Building a Scalable, AI-Enabled AAV Manufacturing Platform: From Molecular Design to Commercial-Ready Production

**Brian Tomkowicz**, SK Pharmteco, USA

## 11:00–11:30 COFFEE BREAK

**11:30–11:50** **Title:** Selective Removal of Early-Eluting Genome-Containing AAV Species with Elevated Residual DNA via Optimized Anion Exchange Chromatography

**Nermin Ibreljic**, Sarepta Therapeutics, USA

**11:50–12:10** **Title:** A Modified CRISPR Approach Using XIST for the Treatment of Down Syndrome

**Volney Sheen**, Harvard Medical School, USA

**12:10–12:30** **Title:** Frontiers of Gene Therapy: Trends and Opportunities from Payload through Scale Up

**Anis H. Khimani**, Antylia Scientific, USA

## PANEL DISCUSSIONS

**12:30–13:10** **Title:** Manufacturing and Supply Chain Strategies

**Michael DiBiasio-White**, ViroSpark BioConsulting, USA

**David Greenwald**, Deerfield Management, USA

**Larry Forman**, CHO Plus, Inc, USA

**Tristan Jervis**, Impact Shine Communications, UK

**Mihir Shukla**, Biopharma Consulting Solutions, LLC, USA

## 13:10–13:30 Closing



**PRISM**

## **PROFESSIONAL CONFERENCE ORGANIZERS**

**Prism Scientific Services Pty Ltd.**, a premier conference organizer, envisions a sustainable future for the Science and Engineering . Our goal is to unite experts and stakeholders through conferences, fostering collaboration and advancing sustainable practices. Committed to curating conferences on engineering and medical sciences, we catalyze the industry's development. Emphasizing interdisciplinary collaboration, our events address complex challenges. Dedicated to sustainability, we minimize footprints and promote eco-friendly venues, inspiring environmental responsibility. As catalysts for positive change, guiding the energy industry toward an innovative, environmentally responsible future in conferences that prioritize sustainable development.

If you are interested in forming a partnership with us for the planning and organization of conferences and events worldwide, please don't hesitate to contact us via email at [writeus@scientificprism.com](mailto:writeus@scientificprism.com) or by phone at **+61 416000202**. Our services extend to facilitating conferences anywhere in the world, and we look forward to the opportunity to discuss your specific needs and requirements.

# **WE WISH TO SEE YOU AT HUMAN GENE THERAPY CONFERENCE-2026**



[chairs@genetherapyconference.com](mailto:chairs@genetherapyconference.com)

Australia: +61 390163202

Prism Scientific Services Pty Ltd

302/480 Collins Street, Melbourne, VIC 3000, Australia

[www.scientificprism.com](http://www.scientificprism.com)

[www.genetherapyconference.com](http://www.genetherapyconference.com)